G1 Therapeutics Inc (NASDAQ:GTHX) Receives $66.67 Average PT from Analysts

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have received a consensus recommendation of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $66.67.

Several research firms have recently weighed in on GTHX. Zacks Investment Research lowered shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. ValuEngine raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. Finally, JPMorgan Chase & Co. raised shares of G1 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $38.00 to $45.00 in a research note on Thursday, August 8th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GTHX. Legal & General Group Plc grew its stake in shares of G1 Therapeutics by 20.0% during the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock valued at $78,000 after purchasing an additional 676 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in G1 Therapeutics by 1,539.2% in the first quarter. BNP Paribas Arbitrage SA now owns 5,098 shares of the company’s stock valued at $85,000 after acquiring an additional 4,787 shares during the last quarter. Bank of Montreal Can boosted its stake in G1 Therapeutics by 93,600.0% in the second quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $86,000 after acquiring an additional 2,808 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in G1 Therapeutics by 18.8% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,166 shares of the company’s stock valued at $97,000 after acquiring an additional 500 shares during the last quarter. Finally, NumerixS Investment Technologies Inc bought a new position in G1 Therapeutics in the first quarter valued at approximately $98,000. 73.58% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ GTHX traded down $0.17 during mid-day trading on Friday, hitting $37.23. 419,200 shares of the stock were exchanged, compared to its average volume of 393,692. The company has a market cap of $1.40 billion, a P/E ratio of -14.54 and a beta of 2.66. The stock’s fifty day simple moving average is $27.83 and its two-hundred day simple moving average is $21.92. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.09). Analysts forecast that G1 Therapeutics will post -3.26 EPS for the current year.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Read More: What does a hold rating mean?

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.